HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $66 to $68.
Read original at benzingaStocks · News reference
JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46
JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and announces Price Target of $46.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 10:40 AM
- Checked
- Jul 15, 2026, 10:40 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $32 to $35.
Read original at benzingaTango Therapeutics Files Prospectus For Up To $400M Common Stock Offering
Up to $400,000,000Common StockWe have previously entered into a Sales Agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, dated November 21, 2025, relating to the sale of shares of our
Read original at benzinga8-K filing — Tango Therapeutics, Inc. (TNGX)
Filed: 2026-08-11 AccNo: 0001193125-26-344997 Size: 154 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar